VAPB and Parkinson disease: Interestingly, the FCA performed with the monoclonal antibody revealed a severe reduction of VAPB fluorescence signals in sALS patients but not in PD patients and HCs, suggesting that VAPB in sALS is post-transcriptionally modified/misfolded that renders the antibody to efficiently bind VAPB in sALS cases.